Logo image of CASI

CASI PHARMACEUTICALS INC (CASI) Stock Fundamental Analysis

NASDAQ:CASI - Nasdaq - KYG1933S1012 - Common Stock - Currency: USD

2.45  -0.01 (-0.41%)

Fundamental Rating

3

Overall CASI gets a fundamental rating of 3 out of 10. We evaluated CASI against 572 industry peers in the Biotechnology industry. CASI may be in some trouble as it scores bad on both profitability and health. CASI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CASI has reported negative net income.
CASI had a negative operating cash flow in the past year.
CASI had negative earnings in each of the past 5 years.
In the past 5 years CASI always reported negative operating cash flow.
CASI Yearly Net Income VS EBIT VS OCF VS FCFCASI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

CASI's Return On Assets of -35.83% is fine compared to the rest of the industry. CASI outperforms 61.28% of its industry peers.
CASI's Return On Equity of -111.60% is in line compared to the rest of the industry. CASI outperforms 42.45% of its industry peers.
Industry RankSector Rank
ROA -35.83%
ROE -111.6%
ROIC N/A
ROA(3y)-34.98%
ROA(5y)-37.53%
ROE(3y)-82.3%
ROE(5y)-73.84%
ROIC(3y)N/A
ROIC(5y)N/A
CASI Yearly ROA, ROE, ROICCASI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100 -100

1.3 Margins

The Gross Margin of CASI (59.17%) is better than 79.04% of its industry peers.
CASI's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CASI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.76%
GM growth 5YN/A
CASI Yearly Profit, Operating, Gross MarginsCASI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K

More info and screens

3

2. Health

2.1 Basic Checks

CASI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CASI has less shares outstanding
The number of shares outstanding for CASI has been increased compared to 5 years ago.
The debt/assets ratio for CASI is higher compared to a year ago.
CASI Yearly Shares OutstandingCASI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
CASI Yearly Total Debt VS Total AssetsCASI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.88, we must say that CASI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.88, CASI is not doing good in the industry: 78.51% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.78 indicates that CASI is somewhat dependend on debt financing.
CASI has a worse Debt to Equity ratio (0.78) than 78.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z -11.88
ROIC/WACCN/A
WACC7.92%
CASI Yearly LT Debt VS Equity VS FCFCASI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 3.55 indicates that CASI has no problem at all paying its short term obligations.
CASI has a Current ratio (3.55) which is in line with its industry peers.
CASI has a Quick Ratio of 2.60. This indicates that CASI is financially healthy and has no problem in meeting its short term obligations.
CASI has a worse Quick ratio (2.60) than 69.27% of its industry peers.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 2.6
CASI Yearly Current Assets VS Current LiabilitesCASI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

CASI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.11%, which is quite impressive.
Looking at the last year, CASI shows a very negative growth in Revenue. The Revenue has decreased by -21.41% in the last year.
The Revenue has been growing by 30.80% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)34.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.14%
Revenue 1Y (TTM)-21.41%
Revenue growth 3Y30.8%
Revenue growth 5YN/A
Sales Q2Q%-11.82%

3.2 Future

Based on estimates for the next years, CASI will show a very strong growth in Earnings Per Share. The EPS will grow by 21.53% on average per year.
CASI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.30% yearly.
EPS Next Y-29.27%
EPS Next 2Y-3.71%
EPS Next 3Y3.74%
EPS Next 5Y21.53%
Revenue Next Year-45.64%
Revenue Next 2Y12.97%
Revenue Next 3Y24.54%
Revenue Next 5Y24.3%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CASI Yearly Revenue VS EstimatesCASI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
CASI Yearly EPS VS EstimatesCASI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CASI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CASI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CASI Price Earnings VS Forward Price EarningsCASI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CASI Per share dataCASI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.71%
EPS Next 3Y3.74%

More info and screens

0

5. Dividend

5.1 Amount

CASI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CASI PHARMACEUTICALS INC

NASDAQ:CASI (2/21/2025, 8:05:15 PM)

2.45

-0.01 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)N/A N/A
Inst Owners26.68%
Inst Owner ChangeN/A
Ins Owners23.58%
Ins Owner Change0%
Market Cap32.83M
Analysts82.86
Price Target6.12 (149.8%)
Short Float %0.65%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.06
Dividend Growth(5Y)N/A
DP-2.74%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.55%
Min EPS beat(2)-83.82%
Max EPS beat(2)38.73%
EPS beat(4)2
Avg EPS beat(4)-16.25%
Min EPS beat(4)-83.82%
Max EPS beat(4)38.73%
EPS beat(8)5
Avg EPS beat(8)-48.99%
EPS beat(12)7
Avg EPS beat(12)-36.1%
EPS beat(16)9
Avg EPS beat(16)-38.55%
Revenue beat(2)0
Avg Revenue beat(2)-22.54%
Min Revenue beat(2)-28.4%
Max Revenue beat(2)-16.69%
Revenue beat(4)0
Avg Revenue beat(4)-14.94%
Min Revenue beat(4)-28.4%
Max Revenue beat(4)-4.59%
Revenue beat(8)3
Avg Revenue beat(8)-2.14%
Revenue beat(12)6
Avg Revenue beat(12)1.29%
Revenue beat(16)9
Avg Revenue beat(16)21.03%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.97
P/FCF N/A
P/OCF N/A
P/B 1.36
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-2.26
EYN/A
EPS(NY)-2.17
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS2.53
BVpS1.8
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.83%
ROE -111.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.17%
FCFM N/A
ROA(3y)-34.98%
ROA(5y)-37.53%
ROE(3y)-82.3%
ROE(5y)-73.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.76%
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.9%
Cap/Sales 6.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.55
Quick Ratio 2.6
Altman-Z -11.88
F-Score4
WACC7.92%
ROIC/WACCN/A
Cap/Depr(3y)381.12%
Cap/Depr(5y)556.34%
Cap/Sales(3y)23.67%
Cap/Sales(5y)107.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.14%
EPS Next Y-29.27%
EPS Next 2Y-3.71%
EPS Next 3Y3.74%
EPS Next 5Y21.53%
Revenue 1Y (TTM)-21.41%
Revenue growth 3Y30.8%
Revenue growth 5YN/A
Sales Q2Q%-11.82%
Revenue Next Year-45.64%
Revenue Next 2Y12.97%
Revenue Next 3Y24.54%
Revenue Next 5Y24.3%
EBIT growth 1Y4.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.32%
OCF growth 3YN/A
OCF growth 5YN/A